Vor Biopharma and Arbor Biotechnologies announced an agreement to use Arbor’s gene editing technologies to engineer hematopoietic stem cells, towards the goal of developing therapies for the treatment of blood cancers, such as acute myeloid leukemia.
1254621 nan items 1 apa default asc 1
AVROBIO, Inc. announced that the European Commission has granted orphan drug designation for AVR-RD-02, the company’s investigational gene therapy for the treatment of Gaucher disease.
Sarepta Therapeutics, Inc. announced positive results from the ongoing study of SRP-9003 the company’s investigational gene therapy for limb-girdle muscular dystrophy Type 2E.
[Sarepta Therapeutics, Inc.]
Sarepta Therapeutics, Inc. announced positive results from the ongoing study of SRP-9003, the company’s investigational gene therapy for limb-girdle muscular dystrophy Type 2E.
[Sarepta Therapeutics, Inc. (GlobeNewswire, Inc.)]
Investigators designed a suicide gene therapy by generating an ARMS-targeted promoter to drive the herpes simplex virus thymidine kinase suicide gene.
[Cancer Gene Therapy]
6445218 XWIWI2N6 items 1 apa default asc 1
A modified human Myogenin promoter that is highly active in alveolar rhabdomyosarcoma | Cancer Gene Therapy. (n.d.). Retrieved September 25, 2020, from https://www.nature.com/articles/s41417-020-00225-0 Cite
Scientists conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 patients who underwent HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning
[Bone Marrow Transplantation]
6445218 W47C58GH items 1 apa default asc 1
Sugita, J., Kamimura, T., Ishikawa, T., Ota, S., Eto, T., Kuroha, T., Miyazaki, Y., Kumagai, H., Matsuo, K., Akashi, K., Taniguchi, S., Harada, M., & Teshima, T. (2020). Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplantation, 1–9. https://doi.org/10.1038/s41409-020-01065-0 Cite
Investigators showed that BATF3 was expressed transiently within the first days after T cell priming and had long-lasting T cell–intrinsic effects.
6445218 8JHVMKUT items 1 apa default asc 1
Ataide, M. A., Komander, K., Knöpper, K., Peters, A. E., Wu, H., Eickhoff, S., Gogishvili, T., Weber, J., Grafen, A., Kallies, A., Garbi, N., Einsele, H., Hudecek, M., Gasteiger, G., Hölzel, M., Vaeth, M., & Kastenmüller, W. (2020). BATF3 programs CD8 + T cell memory. Nature Immunology, 1–11. https://doi.org/10.1038/s41590-020-0786-2 Cite
Researchers generated heterozygous and homozygous conditional inducible knock-in mice expressing a chimeric murine CALR del52 or ins5 with the human mutated C-terminal tail to investigate their pathogenic effects on hematopoiesis.
6445218 KH8IA9J9 items 1 apa default asc 1
Benlabiod, C., Cacemiro, M. da C., Nédélec, A., Edmond, V., Muller, D., Rameau, P., Touchard, L., Gonin, P., Constantinescu, S. N., Raslova, H., Villeval, J.-L., Vainchenker, W., Plo, I., & Marty, C. (2020). Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nature Communications, 11(1), 4886. https://doi.org/10.1038/s41467-020-18691-3 Cite
Twelve patients were treated with nivolumab in the neoadjuvant setting, whereas eight were treated with nivolumab, usually along with other therapies, before undergoing liver transplantation.
6445218 4VUNU4MQ items 1 apa default asc 1
Researchers demonstrated the feasibility of perturbing protein synthesis in a mouse liver by targeting translation elongation factor 2 with RNAi. They were able to achieve over 90% knockdown efficacy and maintain it for two weeks effectively slowing down the rate of translation elongation.
6445218 LFHJQZFY items 1 apa default asc 1
Gerashchenko, M. V., Nesterchuk, M. V., Smekalova, E. M., Paulo, J. A., Kowalski, P. S., Akulich, K. A., Bogorad, R., Dmitriev, S. E., Gygi, S., Zatsepin, T., Anderson, D. G., Gladyshev, V. N., & Koteliansky, V. E. (2020). Translation elongation factor 2 depletion by siRNA in mouse liver leads to mTOR-independent translational upregulation of ribosomal protein genes. Scientific Reports, 10(1), 15473. https://doi.org/10.1038/s41598-020-72399-4 Cite
Scientists highlight potential future innovations that could enhance the efficacy and/or reduce the toxicities associated with CAR T cell therapies.
[Nature Reviews Clinical Oncology]